Amphastar Pharmaceuticals (AMPH) EBT (2013 - 2026)

Amphastar Pharmaceuticals has reported EBT for 14 years, with the latest figure at $38.5 million in Q2 2026.

• On a quarterly basis, EBT fell 2.01% year-over-year to $38.5 million in Q2 2026; TTM through Jun 2026 was $107.4 million, a 35.82% decrease from a year earlier, with the FY2025 full-year figure at $129.0 million, down 33.93% from the prior year.
• EBT was $38.5 million for Q2 2026 at Amphastar Pharmaceuticals, up from $10.1 million in the prior quarter.
• The five-year high for EBT was $63.6 million in Q3 2023, with the low at $10.1 million in Q1 2026.
• Average EBT over 5 years is $37.9 million, with a median of $37.9 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2026: EBT jumped 467.72% in 2022, then sank 67.43% in 2026.
• Over 5 years, EBT stood at $52.4 million in 2022, then fell by 0.98% to $51.9 million in 2023, then retreated by 4.88% to $49.4 million in 2024, then slipped by 24.57% to $37.2 million in 2025, then advanced by 3.5% to $38.5 million in 2026.
• The last three EBT figures came in at $38.5 million (Q2 2026), $10.1 million (Q1 2026), and $37.2 million (Q4 2025), per Business Quant data.